EUVIMEDEUVIMED entdecken
Crossref

Acute cardiotoxicity in pediatric and adolescent patients with solid tumors treated with tyrosine kinase inhibitors

Jessica Gartrell iD, Daniel A Mulrooney, Chia-Wei Hsu, Haitao Pan, Sara M Federico iD, Alberto S Pappo iD, Sara Helmig, Carly J Meredith, Patricia Pease, Anthony M Christensen, Gary Beasley, Michael W Bishop

Cancer · 2025

DOI: 10.1002/cncr.35940 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2025. Verfasst von Jessica Gartrell und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA. Hauptthemen laut MEDLINE: Cardiotoxicity, Neoplasms, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: St. Jude Children's Research Hospital, American Lebanese Syrian Associated Charities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Multitargeted tyrosine kinase inhibitors (MTKIs) have increasingly been used for the treatment of pediatric and young adult patients with solid tumors. Whereas cardiac toxicity is documented in adults, data remain limited in pediatrics. This study sought to characterize the incidence and outcomes of acute cardiotoxicity in pediatric patients with solid tumors treated with an MTKI.

Methods

A retrospective review was conducted of patients who received MTKIs from 2000 to 2021 at St. Jude Children’s Research Hospital. Analyses included patient and disease characteristics, treatment specifics, and measurements of cardiotoxicity (ejection fraction [EF], 2 for left atrial end‐systolic volume index, left ventricular end‐diastolic diameter, and left ventricular end‐systolic diameter). Hypertension (HTN) was evaluated independently, and defined with American Academy of Pediatrics clinical practice guidelines and American College of Cardiology/American Heart Association HTN guidelines.

Results

Among 112 patients, 73 (65%) underwent echocardiography during MTKI therapy. Of 56 patients without prior cardiotoxicity, 17 (32.1%) developed cardiac toxicity during treatment. Of 48 patients without preexisting HTN, 36 (72%) developed HTN at 6 months. Abnormal GLS was the most frequent new‐onset cardiac finding (29.5% at 6 months). Of 61 patients with sequential echocardiograms, 51.4% had a ≥5% decline in EF but only 3.6% required MTKI dose reductions as a result of cardiotoxicity.

Conclusions

Despite changes in cardiac function while on MTKIs, reductions because of cardiac toxicity were infrequent. Routine monitoring of cardiac function during MTKI use and early intervention may enable patients to continue therapy while safeguarding cardiovascular health.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CardiotoxicityNeoplasmsProtein Kinase InhibitorsHumansChildAdolescentFemaleMaleRetrospective StudiesChild, PreschoolEchocardiographyHypertensionInfantIncidenceTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

cardiotoxicitymultitargeted tyrosine kinase inhibitorpediatric oncologypediatric solid tumor

Substanzen

Protein Kinase InhibitorsTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Department of Nursing, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Department of Pediatrics, University of Iowa Stead Family Children's Hospital, Carver College of Medicine, Iowa City, Iowa, USA.

ORCID-Profile: Jessica Gartrell, Sara M Federico, Alberto S Pappo

Förderung

  • St. Jude Children's Research Hospital
  • American Lebanese Syrian Associated Charities

Zitieren

APA

Gartrell, J., Mulrooney, D. A., Hsu, C. W., Pan, H., Federico, S. M., Pappo, A. S., Helmig, S., Meredith, C. J., Pease, P., Christensen, A. M., Beasley, G., & Bishop, M. W. (2025). Acute cardiotoxicity in pediatric and adolescent patients with solid tumors treated with tyrosine kinase inhibitors. Cancer. https://doi.org/10.1002/cncr.35940

Vancouver

Gartrell J, Mulrooney DA, Hsu CW, Pan H, Federico SM, Pappo AS, et al. Acute cardiotoxicity in pediatric and adolescent patients with solid tumors treated with tyrosine kinase inhibitors. Cancer. 2025. doi:10.1002/cncr.35940

BibTeX
@article{Gartrell2025,
  author = {Gartrell, Jessica and Mulrooney, Daniel A and Hsu, Chia-Wei and Pan, Haitao and Federico, Sara M and Pappo, Alberto S and Helmig, Sara and Meredith, Carly J and Pease, Patricia and Christensen, Anthony M and Beasley, Gary and Bishop, Michael W},
  title = {Acute cardiotoxicity in pediatric and adolescent patients with solid tumors treated with tyrosine kinase inhibitors},
  journal = {Cancer},
  year = {2025},
  doi = {10.1002/cncr.35940}
}
Kostenlos starten →